FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2302223557> ?p ?o ?g. }

• W2302223557 endingPage "1675" @default.
• W2302223557 startingPage "1669" @default.
• W2302223557 abstract "Purpose Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs. Patients and Methods Bevacizumab 7.5 mg/kg was administered every 3 weeks for 46 weeks, followed by 24 weeks of surveillance after treatment with the drug. The primary end point was hearing response defined by word recognition score (WRS). Secondary end points included toxicity, tolerability, imaging response using volumetric magnetic resonance imaging analysis, durability of response, and imaging and blood biomarkers. Results Fourteen patients (estimated to yield > 90% power to detect an alternative response rate of 50% at alpha level of 0.05) with NF2, with a median age of 30 years (range, 14 to 79 years) and progressive hearing loss in the target ear (median baseline WRS, 60%; range 13% to 82%), were enrolled. The primary end point, confirmed hearing response (improvement maintained ≥ 3 months), occurred in five (36%) of 14 patients (95% CI, 13% to 65%; P < .001). Eight (57%) of 14 patients had transient hearing improvement above the 95% CI for WRS. No patients experienced hearing decline. Radiographic response was seen in six (43%) of 14 target VSs. Three grade 3 adverse events, hypertension (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related to bevacizumab. Bevacizumab treatment was associated with decreased free vascular endothelial growth factor (not bound to bevacizumab) and increased placental growth factor in plasma. Hearing responses were inversely associated with baseline plasma hepatocyte growth factor (P = .019). Imaging responses were associated with high baseline tumor vessel permeability and elevated blood levels of vascular endothelial growth factor D and stromal cell–derived factor 1α (P = .037 and .025, respectively). Conclusion Bevacizumab treatment resulted in durable hearing response in 36% of patients with NF2 and confirmed progressive VS-associated hearing loss. Imaging and plasma biomarkers showed promising associations with response that should be validated in larger studies." @default.
• W2302223557 created "2016-06-24" @default.
• W2302223557 creator A5003196589 @default.
• W2302223557 creator A5008041103 @default.
• W2302223557 creator A5013091949 @default.
• W2302223557 creator A5015585176 @default.
• W2302223557 creator A5022702941 @default.
• W2302223557 creator A5031920574 @default.
• W2302223557 creator A5043105140 @default.
• W2302223557 creator A5051287778 @default.
• W2302223557 creator A5055973779 @default.
• W2302223557 creator A5059797681 @default.
• W2302223557 creator A5061307417 @default.
• W2302223557 creator A5067944425 @default.
• W2302223557 creator A5068722213 @default.
• W2302223557 creator A5071679104 @default.
• W2302223557 creator A5076205238 @default.
• W2302223557 creator A5082835319 @default.
• W2302223557 date "2016-05-10" @default.
• W2302223557 modified "2023-10-01" @default.
• W2302223557 title "Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas" @default.
• W2302223557 cites W1536400774 @default.
• W2302223557 cites W1908832933 @default.
• W2302223557 cites W1967535091 @default.
• W2302223557 cites W1974629224 @default.
• W2302223557 cites W1975159244 @default.
• W2302223557 cites W1978041336 @default.
• W2302223557 cites W1985968080 @default.
• W2302223557 cites W1990143919 @default.
• W2302223557 cites W1990309105 @default.
• W2302223557 cites W1993016882 @default.
• W2302223557 cites W1996009245 @default.
• W2302223557 cites W1997729527 @default.
• W2302223557 cites W1999205504 @default.
• W2302223557 cites W2022540958 @default.
• W2302223557 cites W2023011946 @default.
• W2302223557 cites W2023247590 @default.
• W2302223557 cites W2049785876 @default.
• W2302223557 cites W2059852545 @default.
• W2302223557 cites W2064339362 @default.
• W2302223557 cites W2083142752 @default.
• W2302223557 cites W2092864149 @default.
• W2302223557 cites W2096415778 @default.
• W2302223557 cites W2100378947 @default.
• W2302223557 cites W2105968454 @default.
• W2302223557 cites W2108073386 @default.
• W2302223557 cites W2113373161 @default.
• W2302223557 cites W2126826184 @default.
• W2302223557 cites W2127440105 @default.
• W2302223557 cites W2133798755 @default.
• W2302223557 cites W2146628652 @default.
• W2302223557 cites W2170249858 @default.
• W2302223557 cites W2218004332 @default.
• W2302223557 cites W2286377525 @default.
• W2302223557 cites W2324041260 @default.
• W2302223557 cites W2326492141 @default.
• W2302223557 cites W4239941686 @default.
• W2302223557 cites W4240574658 @default.
• W2302223557 doi "https://doi.org/10.1200/jco.2015.64.3817" @default.
• W2302223557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4872317" @default.
• W2302223557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26976425" @default.
• W2302223557 hasPublicationYear "2016" @default.
• W2302223557 type Work @default.
• W2302223557 sameAs 2302223557 @default.
• W2302223557 citedByCount "79" @default.
• W2302223557 countsByYear W23022235572016 @default.
• W2302223557 countsByYear W23022235572017 @default.
• W2302223557 countsByYear W23022235572018 @default.
• W2302223557 countsByYear W23022235572019 @default.
• W2302223557 countsByYear W23022235572020 @default.
• W2302223557 countsByYear W23022235572021 @default.
• W2302223557 countsByYear W23022235572022 @default.
• W2302223557 countsByYear W23022235572023 @default.
• W2302223557 crossrefType "journal-article" @default.
• W2302223557 hasAuthorship W2302223557A5003196589 @default.
• W2302223557 hasAuthorship W2302223557A5008041103 @default.
• W2302223557 hasAuthorship W2302223557A5013091949 @default.
• W2302223557 hasAuthorship W2302223557A5015585176 @default.
• W2302223557 hasAuthorship W2302223557A5022702941 @default.
• W2302223557 hasAuthorship W2302223557A5031920574 @default.
• W2302223557 hasAuthorship W2302223557A5043105140 @default.
• W2302223557 hasAuthorship W2302223557A5051287778 @default.
• W2302223557 hasAuthorship W2302223557A5055973779 @default.
• W2302223557 hasAuthorship W2302223557A5059797681 @default.
• W2302223557 hasAuthorship W2302223557A5061307417 @default.
• W2302223557 hasAuthorship W2302223557A5067944425 @default.
• W2302223557 hasAuthorship W2302223557A5068722213 @default.
• W2302223557 hasAuthorship W2302223557A5071679104 @default.
• W2302223557 hasAuthorship W2302223557A5076205238 @default.
• W2302223557 hasAuthorship W2302223557A5082835319 @default.
• W2302223557 hasBestOaLocation W23022235572 @default.
• W2302223557 hasConcept C126322002 @default.
• W2302223557 hasConcept C141071460 @default.
• W2302223557 hasConcept C143998085 @default.
• W2302223557 hasConcept C167734588 @default.
• W2302223557 hasConcept C185592680 @default.
• W2302223557 hasConcept C197934379 @default.
• W2302223557 hasConcept C203092338 @default.

• next